US · INMD
InMode Ltd.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Yokne'am 2069206
- Website
- inmodemd.com
Price · as of 2025-12-31
$14.41
Market cap 871.18M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $56.59 | +292.71% |
| Intrinsic Value(DCF) | $10.45 | -27.48% |
| Graham-Dodd Method(GD) | $17.83 | +23.73% |
| Graham Formula(GF) | $3.19 | -77.83% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.99 | $18.48 | |||
| 2018 | $2.43 | $32.09 | |||
| 2019 | $15.88 | $109.01 | $4,823.89 | $8.24 | $64.73 |
| 2020 | $36.55 | $106.06 | $433.34 | $8.72 | $40.11 |
| 2021 | $36.44 | $73.21 | $2,088.92 | $15.23 | $158.68 |
| 2022 | $31.11 | $63.88 | $609.33 | $16.52 | $66.50 |
| 2023 | $21.97 | $58.97 | $170.91 | $21.27 | $38.30 |
| 2024 | $19.02 | $53.81 | $8.30 | $20.30 | $0.00 |
| 2025 | $13.64 | $56.59 | $8.17 | $17.83 | $3.19 |
AI valuation
Our deep-learning model estimates InMode Ltd.'s (INMD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $56.59
- Current price
- $14.41
- AI upside
- +292.71%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.45
-27.48% upside
Graham-Dodd
$17.83
+23.73% upside
Graham Formula
$3.19
-77.83% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INMD | InMode Ltd. | $14.41 | 871.18M | +293% | -27% | +24% | -78% | 9.40 | 1.29 | 2.38 | 3.06 | — | 1.29 | 78.54% | 23.05% | 25.33% | 13.53% | 56.67% | 12.09% | 0.02 | — | 9.88 | 8.55 | -2.61 | -3644.00% | -616.00% | -3615.00% | 9.56% | 1.21 | 65.78% | 0.00% | 0.00% | 30.54% | 3.98 | 4.03 | 0.92 | 9.96 |
| AHCO | AdaptHealth Corp. | $9.15 | 1.24B | +239% | -53% | — | — | -19.73 | 0.86 | 0.40 | 2.75 | — | -1.18 | 17.52% | 5.74% | -2.18% | -4.27% | 7.18% | -1.50% | 0.12 | 1.76 | 1.02 | 0.67 | 0.16 | -18525.00% | -49.00% | -696.00% | 16.84% | 0.84 | 8.45% | 0.00% | 0.00% | 148.90% | 7.43 | 6.31 | 0.43 | 0.97 |
| ANAB | AnaptysBio, Inc. | $55.05 | 1.52B | -23% | +23,485% | — | — | -3.19 | 6.54 | 5.08 | -4.83 | — | 6.54 | -79.49% | -125.93% | -159.10% | -182.71% | 99.94% | -31.02% | 5.21 | -2.29 | 9.51 | 9.38 | -2.66 | -1579.00% | 43203.00% | 1158.00% | -29.26% | -2.98 | 117.98% | 0.00% | 0.00% | 0.10% | -3.90 | -3.30 | 4.91 | -1.16 |
| AXGN | AxoGen, Inc. | $31.73 | 1.59B | +57% | -27% | -97% | — | -89.88 | 10.95 | 6.27 | 7266.33 | -187.94 | 11.56 | 74.31% | -3.49% | -6.97% | -13.49% | -6.24% | -7.38% | 0.15 | -1.02 | 5.11 | 2.62 | -84.93 | 4783.00% | 2021.00% | -2676364.00% | -0.21% | 0.03 | -2.33% | 0.00% | 0.00% | 4.07% | -177.75 | -475.67 | 6.19 | 8.61 |
| CTEV | Claritev Corporation | $13.47 | 222.6M | +1,151% | -57% | — | — | -0.83 | -1.36 | 0.25 | 10.21 | — | -0.05 | 27.61% | 4.67% | -29.45% | 632.60% | 0.76% | -5.66% | -26.64 | 0.11 | 0.86 | 0.59 | 9.71 | -8303.00% | 374.00% | 1685.00% | -5.18% | 0.45 | -0.27% | 0.00% | 0.00% | 0.00% | 107.70 | -395.26 | 5.03 | -0.45 |
| IART | Integra LifeSciences Hold… | $11.38 | 886.41M | +457% | -63% | — | — | -1.55 | 0.77 | 0.49 | -1.58 | -0.02 | -1.13 | 51.69% | -30.17% | -31.58% | -39.90% | -21.27% | -13.52% | 0.21 | -5.72 | 2.54 | 1.19 | 0.04 | 736120.00% | 153.00% | -22439.00% | -3.88% | 0.11 | -1.46% | 0.00% | 0.00% | 219.53% | -1.53 | -24.24 | 0.46 | 0.59 |
| IRMD | IRadimed Corporation | $103.53 | 1.32B | -46% | -36% | — | -72% | 33.89 | 7.51 | 8.90 | 26.33 | 305.02 | 7.79 | 76.94% | 29.99% | 26.26% | 24.31% | 59.56% | 20.20% | 0.00 | — | 8.84 | 7.38 | -2.29 | 1111.00% | 1171.00% | 22283.00% | 2.70% | 3.01 | 60.30% | 2.10% | 71.10% | 2.77% | 27.31 | 34.04 | 8.19 | 37.09 |
| OCS | Oculis Holding AG | $29.41 | 1.68B | — | — | — | — | -7.08 | 8.29 | 886.66 | -7.02 | — | 10.12 | -7492.27% | -10671.14% | -12503.94% | -102.85% | 682.30% | -73.23% | 0.02 | — | 2.37 | 2.25 | 0.36 | -2862.00% | — | -1144.00% | -7.85% | -1.07 | 445.69% | 0.00% | 0.00% | 0.00% | -6.98 | -10.70 | 744.55 | 3.05 |
| OPK | OPKO Health, Inc. | $1.20 | 921.24M | +2,047% | -57% | — | +48% | -4.21 | 0.75 | 1.56 | -20.44 | -1.44 | 3.55 | 61.01% | -36.08% | -37.20% | -17.14% | -14.89% | -10.92% | 0.33 | -2.16 | 3.97 | 3.13 | -0.89 | 29113.00% | -1490.00% | -848.00% | -20.10% | -1.22 | -13.88% | 0.00% | 0.00% | 3.09% | -4.53 | -5.20 | 1.64 | -0.35 |
| TNDM | Tandem Diabetes Care, Inc… | $25.30 | 1.72B | +78% | -60% | — | — | -8.29 | 10.94 | 1.67 | -10.59 | -7.76 | 10.94 | 52.31% | -7.70% | -20.17% | -97.88% | -25.81% | -22.15% | 2.86 | -9.88 | 2.55 | 1.89 | -2.03 | 10680.00% | 793.00% | -69409.00% | -1.75% | -0.04 | -9.80% | 0.00% | 0.00% | 2.97% | -23.67 | -62.33 | 1.82 | 0.78 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
- CEO
- Moshe Mizrahy
- Employees
- 599
- Beta
- 2.17
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.45 ÷ $14.41) − 1 = -27.48% (DCF, example).